anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ankylosing spondylitis (AS) is an autoimmune disease, and the relationship between copper death and AS is not clear. The aim of this study was to analyze and identify potential cuprosis-related genes associated with the onset of AS by bioinformatics methods. We obtained the AS gene expression profile GSE25101 from the Gene Expression Omnibus (GEO) database, which consists of blood samples from 16 active AS patients and 16 sex-and age-matched controls. After analyzing the data, we utilized the WGCNA method to identify genes that exhibited significant differential expression. In order to assess the prognostic and predictive power of these genes, we constructed receiver operating characteristic (ROC) curves. To further validate our predictions, we employed nomograms, calibration curves, decision curve analysis, and external datasets. Lastly, we conducted an analysis on immune infiltration and explored the correlation between key genes and immune response. Three genes, namely INPP5E, CYB5R1, and HGD, have been identified through analysis to be associated with AS. The diagnosis of patients using these genes has been found to possess a high level of accuracy. The area under the ROC curve is reported to be 0.816 for INPP5E, 0.879 for CYB5R1, and also 0.879 for HGD. Furthermore, the nomogram demonstrates an excellent predictive power, and it has been calibrated using a Calibration curve. Its clinical usefulness and net benefit have been thoroughly analyzed and estimated through the use of a DCA curve. Moreover, INPP5E, CYB5R1, and HGD are found to be associated with various types of immune cells. In conclusion, the systematic analysis of cuprosis-related genes may aid in the identification of mechanisms related to copper-induced cell death in AS and offer valuable biomarkers for the diagnosis and treatment of AS.
High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases. However, the associated high expenses, radiation exposure , and its limited possibility for bedside use are a limitation. Transthoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases. Its non invasive nature , relatively low price ,portability for bedside use, and high reproducibility of results allows for incorporation of imaging findings with clinical data. Although Transthoracic ultrasonograghy is not an alternative to High resolution computed tomography,it can potentially provide useful supplemental information in certain specific situations ,such as for rapid bedside diagnostic assessment of dyspneic patients. B-line is a common and significant abnormal sign used for diagnostic appraisal by Transthoracic ultrasonograghy, but it cannot define the exact underlying pathologic feature on a lung ultrasound. When the lung parenchymal pathology reaches the lung surface ,certain characteristic changes of the pleural line can be detected by means of the good imaging made possible by high-resolution Transthoracic ultrasonograghy ,but the application and strength of pleural line abnormalities in the differential diagnosis of lung diseases has not been adequately explored . Existing literature on the illustration of the pleural line is scarce ,and the shape of pleural line has not been adequately investigated and described ,especially in comparison with Computed tomography findings. Most studies that have investigated pleural lines are confined to the sub population with interstitial lung diseases.
The investigator will evaluate the side effects of oliceridine. Limited information suggests that oliceridine may cause fewer side effects than the standard opioids given post surgery. Oliceridine is effective for treating acute pain, and is approved by the FDA. Patients will wear a device that continuously monitors breathing. Data from this monitor will be blinded to the clinical staff. Primary Aims include: The investigators will evaluate the proportion of patients having an adjudicated meaningful respiratory compromise with a specified precision of 0.15 using a 95% confidence interval at 24 hours post first study dose.
<P>PROBLEM TO BE SOLVED: To provide a cold sense agent composition imparting a sufficient refrigerant feeling without an irritant feeling over a long period and a cold sense cosmetic using the cold sense agent composition.  <P>SOLUTION: The cold sense agent composition is characterized as formulating 100 pts. of menthol with 1-30 pts. of isopulegol, 0.1-10 pts. of camphor, 1-30 pts. of monoglycol salicylate and 10-200 pts. of a skin penetrant. For further detail, the skin penetrant is one or more kinds of substances selected from diisopropyl adipate, diisopropyl sebacate and diethyl sebacate. The cold sense cosmetic comprises 0.1-50% of the cold sense agent composition.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The majority of new HIV infections are transmitted through heterosexual contact. Currently, there is no single product that is completely efficacious in preventing initial HIV infection through vaginal transmission. Thus, the development of a topical product which could block local virus replication once infection has occurred is needed. Topical microbicides are designed to prevent the sexual transmission of HIV and other disease pathogens. Potentially, they can be applied vaginally to prevent both male-to-female and female-to-male transmission. They also offer a female-controlled option. PMPA gel has shown some activity against HIV and STD pathogens in in vitro and in vivo laboratory studies.

Participants undergo eligibility screening tests which include: a general physical exam; a pelvic exam; a urine pregnancy test; urinalysis; HIV and STD testing and counseling; and hematology, liver, and renal function tests. For HIV-infected participants, a CD4 cell count is performed and specimens are collected for quantitation of HIV viral load in plasma and cervico-vaginal fluids. \[AS PER AMENDMENT 05/29/02: and for HIV resistance genotyping.\] PMPA gel is evaluated among 4 types of women distributed into 7 cohorts. All participants apply PMPA gel intravaginally for 14 consecutive intramenstrual days. The dose and frequency of application is escalated across "cohorts." Cohorts A1 through A4 consist of HIV-uninfected, abstinent women who use different doses of PMPA gel once or twice daily. Cohort B includes HIV-uninfected women who are sexually active. Cohorts C and D consist of HIV-infected women who are abstinent or sexually active, respectively. Cohorts B, C, and D use the highest practical dose frequency. The male partners of sexually active participants undergo HIV and STD testing and counseling as well as an optional genital exam and a post-regimen interview. Participants keep a daily record of when doses are taken and of any adverse effects. Pelvic exams, and hematology, liver, and renal function tests (and CD4 cell counts \[AS PER AMENDMENT 05/29/02: and resistance genotyping\] in HIV-infected participants) are performed at follow-up visits. After the regimen is complete, participants participate in group interviews to discuss adverse effects, adherence to, and general perception of PMPA gel.

The first 6 participants in Cohorts A2, B, and C take part in a pharmacokinetic (PK) study of PMPA gel. Serum collection and PK analysis are performed at different time intervals during 2 study visits.
PURPOSE: A composition and a cosmetic composition containing an Inulae radix extract are provided to suppress the growth of pancreatic cancer cells, and to induce the apoptosis of the pancreatic cancer cells. CONSTITUTION: A composition for treating pancreatic cancer contains an Inulae radix extract as an active ingredient, which is prepared using an organic solvent. The organic solvent is ethanol. The ethanol extract is extracted at 50 deg. C for 24 hours, and dried and concentrated at 45 deg. C. The composition contains a pharmaceutically acceptable carrier or a diluent. The pancreatic cancer is pancreatic ductal adenocarcinoma. [Reference numerals] (AA) Relative cell viability
Mechanism of Action: Clotrimazole is an imidazole antifungal agent. Imidazoles inhibit 14-(-demethylation of lanosterol in fungi by binding to one of the cytochrome P-450 enzymes. This leads to the accumulation of 14-(-methylsterols and reduced concentrations of ergosterol, a sterol essential for a normal fungal cytoplasmic membrane. The methylsterols may affect the electron transport system, thereby inhibiting growth of fungi.

Activity In Vivo: Clotrimazole has been shown to be active against most strains of the following dermatophytes, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section: Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum.

Activity In Vitro: In vitro, clotrimazole has been shown to have activity against many dermatophytes, but the clinical significance of this information is unknown.

Drug Resistance: Strains of dermatophytes having a natural resistance to clotrimazole have not been reported. Resistance to azoles including clotrimazole has been reported in some Candida species.

No single-step or multiple-step resistance to clotrimazole has developed during successive passages of Trichophyton mentagrophytes.
Rezvilutamide 240 mg orally once a day. Patients should also receive androgen deprivation therapy, which includes both gonadotropin releasing hormone analogue (GnRHa) castration treatment or bilateral orchiectomy.
Described is a cream of topic application, for the face, neck and hands, which regenerates the skin and reduces wrinkles and hyperpigmentation. The oily ingredients of the composition are: Cetyl alcohol, almond oil, grape seed oil, lanoline, stearic acid, vitamin E and propylparaben. The aqueous components are: Methylparaben, glycerine, water of roses, aqueous solution of the methanolic extract resulting from the aerial part of Echeveria gigantea and trietanolamine. The components are combined and heated. The preparation is cooled until reaching a room temperature and then is ready to be topically applied. It may be used during the day and night and as a makeup base.
Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole. Some examples of drugs for which plasma concentrations increase are: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, finerenone, voclosporin. In addition, coadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. (See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. Some specific examples are listed in PRECAUTIONS: Drug Interactions.

Coadministration with venetoclax is contraindicated in patients with CLL/SLL during the dose initiation and ramp-up phase of venetoclax due to the potential for an increased risk of tumor lysis syndrome.

Itraconazole should not be administered for the treatment of onychomycosis to pregnant patients or to women contemplating pregnancy.

Itraconazole is contraindicated for patients who have shown hypersensitivity to itraconazole. There is limited information regarding cross-hypersensitivity between itraconazole and other azole antifungal agents. Caution should be used when prescribing itraconazole to patients with hypersensitivity to other azoles.
The present invention relates to specialized therapies capable of solving wound-healing problems in an efficient and accessible manner, presenting a formulated curative composition for topical application. Herein, it is a widespread problem in the comprehensive management of wounds. The difficulties that patients show in certain metabolic and infectious conditions make the healing process torpid and chronic, mainly varicose ulcers and lesions caused by infectious processes that are difficult to heal, which even infect deeper tissues, such as bone, thus reducing patients' quality of life and health. Said composition contains pine nut essential oil, an antioxidant, essential oils of vegetable resins, an antimicrobial agent, and an adhesive agent to treat wounds with a vast effective antiseptic and therapeutic potential, increasing the curative function. Also, it discloses a manufacturing procedure consisting of a first stage, which refers to the extraction of terpenoids and their deriva tives, the extraction of flavonoids from jatropha curcas plant shrubs, and the extraction of flavonoids from pine trees, and the method of preparing the wound healing composition. Further, it has its field of action within the use of healing and anti-infective of botanical origin based on pine nut essential oil, associated with a group of solvents, mainly containing phenols and terpenoids with active principles product of secondary plant metabolism, related to essential oils.
BACKGROUND: Across the world, 25-29% of the population suffer from pain. Pain is the most frequent reason for an emergency department (ED) visit. This symptom is involved in approximately 70% of all ED visits. The effective management of acute pain with adequate analgesia remains a challenge, especially for severe pain. Intravenous (IV) morphine protocols are currently indicated. These protocols are based on patient-reported scores, most often after an immediate evaluation of pain intensity at triage. However, they are not systematically prescribed. This aspect could be explained by the fact that physicians individualize opioid pain management for each patient and each care pathway to determine the best benefit-risk balance. Few data are available regarding bedside organizational factors involved in this phenomenon.
OBJECTIVE: This study aimed to analyze the organizational factors associated with no IV morphine prescription in a standardized context of opioid management in a tertiary-care ED.
METHODS: A 3-month prospective study with a case-control design was conducted in a French university hospital ED. This study focused on factors associated with protocol avoidance despite a visual analog scale (VAS) ≥60 or a numeric rating scale (NRS) ≥6 at triage. Pain components, physician characteristics, patient epidemiologic characteristics, and care pathways were considered. Qualitative variables (percentages) were compared using Fisher's exact test or the chi-squared tests. Student's t-test was used to compare continuous variables. The results were expressed as means with their standard deviation (SD). Factors associated with morphine avoidance were identified by logistic regression.
RESULTS: A total of 204 patients were included in this study. A total of 46 cases (IV morphine) and 158 controls (IV morphine avoidance) were compared (3:1 ratio). Pain patterns and patient's epidemiologic characteristics were not associated with an IV morphine prescription. Regarding NRS intervals, the results suggest a practice disconnected from the patient's initial self-report. IV morphine avoidance was significantly associated with care pathways. A significant difference between the IV morphine group and the IV morphine avoidance group was observed for "self-referral" [adjusted odds ratio (aOR): 5.11, 95% CIs: 2.32-12.18, p < 0.0001] and patients' trajectories (Fisher's exact test; p < 0.0001), suggesting IV morphine avoidance in ambulatory pathways. In addition, "junior physician grade" was associated with IV morphine avoidance (aOR: 2.35, 95% CIs: 1.09-5.25, p = 0.03), but physician gender was not.
CONCLUSION: This bedside case-control study highlights that IV morphine avoidance in the ED could be associated with ambulatory pathways. It confirms the decreased choice of "NRS-only" IV morphine protocols for all patients, including non-trauma patterns. Modern pain education should propose new tools for pain evaluation that integrate the heterogeneity of ED pathways.
In the My Dia-RNP group, participants will undergo the pre-RNP assessment 2 weeks before Ramadan. They will be given a nutrition education based on the Ramadan Nutrition Plan Guide published by IDF-DAR Practical Guidelines. They will also be asked to incorporate diabetes-specific nutrition formula (Nutren untuk Diabetik®) within the prescribed calories before Ramadan period to help them familiarise with a dietary change.
The invention provides a technique for allowing unstructured information to be communicated, and for allowing the receiver of that unstructured information to convert it into structured information for relatively effective, rapid, and reliable classification. Unstructured information is received and processed by a system performing a selected protocol, and in which the selected protocol determines a set of follow-on requests for information with which to respond to the unstructured information. The follow-on requests for information, and responses thereto, allow the receiver to classify and structure the originally unstructured information, and to make a response that is appropriate to the originally unstructured information. The system performing the selected protocol includes a customer (patient) client device, such as the "Health Buddy" device described in the Incorporated Disclosures, capable of communicating with a provider server device, such as the information clearinghouse described in the Incorporated Disclosures. The client device can be augmented by: patient sensors, patient-initiated communication elements, and transportable patient miniclient devices. Patient sensors can monitor or sense medical information (such as blood gas data, blood glucose data, or weight) or patient compliance with a medical regimen (such as use of prescribed medication). Patient-initiated communication elements an send information to the provider without prompting by the provider (such as when the patient has a question, when the patient thinks there is an alert condition, or when the patient sensors detect a possible alert condition). Transportable patient miniclient devices can sense and record information for the patient (such as blood gas data or heartbeat), so as to send that information to the provider when later coupled to the patient client device, and can provide a communication channel for alert messages.
There are multiple skeletal maturity measures currently in use which were established with reliability in assessing growth. The advantages and shortcomings of each index was previously examined. This study aims to explore the use of proximal femoral epiphysis, which is in close proximity of the radiographic field of the spine, in assessing the growth status of patients with idiopathic scoliosis. The stages of the proximal femoral epiphyseal ossification has been established with specific definitions. The reliability and reproducibility of using these gradings will be examined by orthopaedic surgeons. Subsequently, the assessment of different pubertal growth landmarks using these gradings will be validated, and to see whether these gradings can provide indications of peak growth and growth cessation. Finally, the relationships of such growth assessment using this proximal femoral epiphysis ossification (PFEO) system and the curve progression in idiopathic scoliosis will be studied.
Leukostasis is a classic and well-known complication of acute leukemia when major hyperleukocytosis is present. It affects some organs, notably the central nervous system. The symptoms of cerebral leukostasis are diverse and vary in intensity. Diagnosis of such a condition is iconographic. Treatment relies mainly on two aspects: preventing complications and chemical or mechanical cytoreduction. Currently, the prognosis of patients with cerebral leukostasis is uncertain, although quick resolution of neurological signs is sometimes observed after treatment is initiated.
Drug-induced Torsade de Pointes (TdP), a life-threatening polymorphic ventricular tachyarrhythmia, emerges due to the cardiotoxic effects of pharmaceuticals. The need for precise mechanisms and clinical biomarkers to detect this adverse effect presents substantial challenges in drug safety assessment. In this study, we propose that analyzing the physicochemical properties of pharmaceuticals can provide valuable insights into their potential for torsadogenic cardiotoxicity. Our research centers on estimating TdP risk based on the molecular structure of drugs. We introduce a novel quantitative structure-toxicity relationship (QSTR) prediction model that leverages an in silico approach developed by adopting the 4R rule in laboratory animals. This approach eliminates the need for animal testing, saves time, and reduces cost. Our algorithm has successfully predicted the torsadogenic risks of various pharmaceutical compounds. To develop this model, we employed Support Vector Machine (SVM) and ensemble techniques, including Random Forest (RF), Extreme Gradient Boosting (XGBoost), and Categorical Boosting (CatBoost). We enhanced the model's predictive accuracy through a rigorous two-step feature selection process. Furthermore, we utilized the SHapley Additive exPlanations (SHAP) technique to explain the prediction of torsadogenic risk, particularly within the RF model. This study represents a significant step towards creating a robust QSTR model, which can serve as an early screening tool for assessing the torsadogenic potential of pharmaceutical candidates or existing drugs. By incorporating molecular structure-based insights, we aim to enhance drug safety evaluation and minimize the risks of drug-induced TdP, ultimately benefiting both patients and the pharmaceutical industry.
Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.